How many 8-K filings has Rocket Pharmaceuticals, Inc. filed?

Rocket Pharmaceuticals, Inc. (RCKTW) has 32 8-K (Current Event Report) filings on record, spanning Feb 2024 to Nov 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Rocket Pharmaceuticals, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Rocket Pharmaceuticals, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Rocket Pharmaceuticals, Inc. (RCKTW) — 8-K Filings

All 8-K filings from Rocket Pharmaceuticals, Inc.. Browse 32 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (32)

8-K Filing — Nov 6, 2025
Rocket Pharmaceuticals Files 8-K — Oct 14, 2025 Risk: low
Rocket Pharmaceuticals, Inc. filed an 8-K on October 14, 2025, reporting other events and financial statements. The company, formerly known as Inotek Pharmaceut
Rocket Pharmaceuticals Files 8-K: Other Events — Oct 3, 2025 Risk: medium
Rocket Pharmaceuticals, Inc. filed an 8-K on October 3, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these e
Rocket Pharmaceuticals Announces Board and Officer Changes — Sep 29, 2025 Risk: medium
On September 23, 2025, Rocket Pharmaceuticals, Inc. reported changes in its board of directors and executive officers. The filing indicates the election of new
Rocket Pharmaceuticals Files 8-K for Material Agreement — Sep 17, 2025 Risk: medium
Rocket Pharmaceuticals, Inc. filed an 8-K on September 17, 2025, reporting an entry into a material definitive agreement on September 11, 2025. The filing also
Rocket Pharmaceuticals Reports Officer and Director Changes — Aug 25, 2025 Risk: medium
Rocket Pharmaceuticals, Inc. filed an 8-K on August 25, 2025, reporting changes effective August 20, 2025. The filing pertains to the departure of directors or
Rocket Pharmaceuticals Files 8-K — Aug 20, 2025 Risk: low
On August 20, 2025, Rocket Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material
Rocket Pharmaceuticals Files 8-K: Operations, Personnel Changes — Aug 7, 2025 Risk: medium
Rocket Pharmaceuticals, Inc. filed an 8-K on August 7, 2025, reporting on its results of operations and financial condition as of August 4, 2025. The filing als
Rocket Pharmaceuticals Files 8-K — Jul 24, 2025 Risk: low
On July 24, 2025, Rocket Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No spe
Rocket Pharmaceuticals Reports Exit/Disposal Costs — Jul 23, 2025 Risk: medium
Rocket Pharmaceuticals, Inc. filed an 8-K on July 23, 2025, reporting on cost associated with exit or disposal activities. The filing does not specify any dolla
Rocket Pharmaceuticals Files 8-K — Jul 17, 2025 Risk: low
Rocket Pharmaceuticals, Inc. filed an 8-K on July 17, 2025, reporting other events and financial statements. The company, formerly known as Inotek Pharmaceutica
Rocket Pharmaceuticals Announces Executive and Board Appointments — Jul 11, 2025 Risk: medium
Rocket Pharmaceuticals, Inc. announced on July 7, 2025, a series of executive and board changes. Dr. Jonathan Leff has been appointed as Chief Medical Officer,
Rocket Pharmaceuticals Files 8-K on Shareholder Votes — Jun 18, 2025 Risk: low
Rocket Pharmaceuticals, Inc. filed an 8-K on June 18, 2025, to report on the submission of matters to a vote of its security holders. The filing indicates that
Rocket Pharmaceuticals Files 8-K — May 27, 2025 Risk: low
Rocket Pharmaceuticals, Inc. filed an 8-K on May 27, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The filing confirms the
Rocket Pharmaceuticals Files 8-K — May 15, 2025 Risk: low
Rocket Pharmaceuticals, Inc. filed an 8-K on May 15, 2025, reporting on other events and financial statements. The filing does not contain specific financial fi
Rocket Pharmaceuticals Files 8-K on Financials — May 8, 2025 Risk: low
Rocket Pharmaceuticals, Inc. filed an 8-K on May 8, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Ex
Rocket Pharmaceuticals Reports Officer/Director Changes — Apr 29, 2025 Risk: medium
Rocket Pharmaceuticals, Inc. filed an 8-K on April 29, 2025, reporting changes effective April 26, 2025. The filing indicates a departure of directors or certai
Rocket Pharmaceuticals Reports Leadership and Compensation Changes — Apr 7, 2025 Risk: medium
Rocket Pharmaceuticals, Inc. filed an 8-K on April 7, 2025, reporting changes in its board of directors and executive officers, as well as updates to compensato
Rocket Pharmaceuticals Files 8-K for Financials — Feb 27, 2025 Risk: low
Rocket Pharmaceuticals, Inc. filed an 8-K on February 27, 2025, to report on its results of operations and financial condition, and to file financial statements
Rocket Pharmaceuticals Elects New Directors — Jan 28, 2025 Risk: low
Rocket Pharmaceuticals, Inc. announced on January 25, 2025, a change in its board of directors. Specifically, the company elected two new directors, Dr. Jonatha
Rocket Pharmaceuticals Enters Material Definitive Agreement — Dec 12, 2024 Risk: medium
Rocket Pharmaceuticals, Inc. announced on December 9, 2024, that it entered into a material definitive agreement. The company, formerly known as Inotek Pharmace
Rocket Pharma Elects Biopharma Veteran Epstein to Board — Dec 5, 2024 Risk: low
Rocket Pharmaceuticals, Inc. announced on December 2, 2024, the election of Dr. David M. Epstein to its Board of Directors. Dr. Epstein brings extensive experie
Rocket Pharmaceuticals Files 8-K — Nov 18, 2024 Risk: low
Rocket Pharmaceuticals, Inc. filed an 8-K on November 18, 2024, to report on other events and financial statements. The filing does not disclose specific new ma
Rocket Pharmaceuticals Files 8-K — Nov 7, 2024 Risk: low
Rocket Pharmaceuticals, Inc. filed an 8-K on November 7, 2024, reporting on its results of operations and financial condition, as well as financial statements a
Rocket Pharma Appoints New CMO, Director; Discloses Comp — Sep 11, 2024 Risk: medium
Rocket Pharmaceuticals, Inc. announced on September 5, 2024, the appointment of Dr. Jonathan Leff as Chief Medical Officer and the election of Ms. Sarah Kelly t
Rocket Pharmaceuticals Files 8-K on Financials — Aug 5, 2024 Risk: low
Rocket Pharmaceuticals, Inc. filed an 8-K on August 5, 2024, reporting on its results of operations and financial condition. The filing includes financial state
Rocket Pharmaceuticals Files 8-K — Jun 28, 2024 Risk: low
Rocket Pharmaceuticals, Inc. filed an 8-K on June 28, 2024, reporting other events and financial statements. The company, formerly known as Inotek Pharmaceutica
Rocket Pharmaceuticals Files 8-K on Corporate Matters — Jun 20, 2024 Risk: low
Rocket Pharmaceuticals, Inc. filed an 8-K on June 20, 2024, reporting events that occurred on June 13, 2024. The filing indicates a change in the company's fisc
Rocket Pharmaceuticals Files 8-K for Operations Update — May 6, 2024 Risk: low
Rocket Pharmaceuticals, Inc. filed an 8-K on May 6, 2024, to report on its results of operations and financial condition, as well as to file financial statement
Rocket Pharmaceuticals Files 8-K with Officer/Director Changes — Mar 29, 2024 Risk: medium
Rocket Pharmaceuticals, Inc. filed an 8-K on March 29, 2024, reporting changes effective March 25, 2024. The filing indicates a departure of directors or certai
Rocket Pharma Files 8-K on Financial Condition and Operations — Feb 26, 2024 Risk: low
Rocket Pharmaceuticals, Inc. filed an 8-K on February 26, 2024, reporting on its results of operations and financial condition. The filing, under SEC File Numbe
Rocket Pharma Files Routine 8-K; Event Details Not Disclosed — Feb 13, 2024 Risk: low
Rocket Pharmaceuticals, Inc. filed a Form 8-K with the SEC on February 13, 2024, reporting 'Other Events' and 'Financial Statements and Exhibits.' The filing, u

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX